NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 1.2021.
Jennifer M. Weiss, Samir Gupta, Carol A. Burke, Lisen Axell, Lee-may Chen, Daniel C. Chung, Katherine M Clayback, Susan Dallas, Seth Felder, Olumide B. Gbolahan, Francis M. Giardiello, William M. Grady, Michael J. Hall, Heather Hampel, Rachel Hodan, Gregory Idos, Priyanka Kanth, Bryson W. Katona, Laura W. Lamps, Xavier Llor, Patrick M Lynch, Arnold J. Markowitz, Sara Pirzadeh‐Miller, N. Jewel Samadder, David Shibata, Benjamin Swanson, Brittany M. Szymaniak, Georgia L. Wiesner, Andrew M. D. Wolf, Matthew B. Yurgelun, Mae Zakhour, Susan Darlow, Mary A. Dwyer, Mallory Campbell
Abstract
Identifying individuals with hereditary syndromes allows for timely cancer surveillance, opportunities for risk reduction, and syndrome-specific management. Establishing criteria for hereditary cancer risk assessment allows for the identification of individuals who are carriers of pathogenic genetic variants. The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal provides recommendations for the assessment and management of patients at risk for or diagnosed with high-risk colorectal cancer syndromes. The NCCN Genetic/Familial High-Risk Assessment: Colorectal panel meets annually to evaluate and update their recommendations based on their clinical expertise and new scientific data. These NCCN Guidelines Insights focus on familial adenomatous polyposis (FAP)/attenuated familial adenomatous polyposis (AFAP) syndrome and considerations for management of duodenal neoplasia.